VPT:CC - Ventripoint Welcomes Dr. Jose Banchs as New Clinical Advisor
(TheNewswire)
Toronto, Ontario – TheNewswire –April 27, 2022 - Ventripoint Diagnostics Ltd.(" Ventripoint " or the " Company "), (TSXV:VPT ) ; ( OTC:VPTDF) is excited to have Dr. Jose Banchs join its Boardof Clinical Advisors.
Dr. Banchs has been involved with Ventripoint’sdevelopment for the past few years and will now take on a leadershiprole for clinical development. Dr. Banchs is the current Director ofEchocardiography at the University of Colorado’s Anschutz MedicalCampus as well as a Professor of Medicine in the Cardiology Divisionat the University of Colorado. He is a diplomate of the American Boardof Internal Medicine in Cardiovascular Disease and the National Boardof Echocardiography.
Dr. Banchs has been a consultant for numerousorganizations across the United States over the years. His extensiveexperience and excellence in both research and teaching has earned himmany honors and awards. He has been recognized as TX Top Doctor 2020and 2019, received the Faculty Teacher of the Year Award for multipleyears in a row and in 2021 was the recipient of the ASE MeritoriousService Award.
Dr. Banchs has an extensive list of published workwithin the biomedical field, such as research articles, book chapters,and abstracts. Based on 2018 data, there are 2,380 deaths fromcardiovascular disease each day in the US. Ventripoint aims to bring afaster and reliable diagnostic tool for cardiac disease with the helpof experts like Dr. Banchs. Dr. Banchs will bring the insight he hasgained as a top doctor in the cardiology field as well as the latestresearch in cardiology developments to Ventripoint.
“I am excited to join Ventripoint clinical advisoryboard at a time when there is great progress and innovation in thearea of cardiac imaging. I believe Ventripoint’s Knowledge BasedReconstruction (KBR) technology is unique and provides the imagingclinicians with an unparallel escalation of precision and overallimaging quality at their fingertips. The concept and implementationare revolutionary, improves our interpretation confidence and willultimately help improve our patient care.” stated Dr. Banchs.
About Ventripoint DiagnosticsLtd.
Ventripoint has become anindustry leader in the application of AI (Artificial Intelligence) toechocardiography. Ventripoint's VMS products are powered by itsproprietary KBR technology, which is the result of a decade ofdevelopment and provides accurate volumetric cardiac measurementsequivalent to MRI. This affordable, gold-standard alternative allowscardiologists greater confidence in the management of their patients.Providing better care to patients serves as a springboard and basicstandard for all of Ventripoint's products that guide our futuredevelopments. In addition, VMS+ is versatile and can be used with allultrasound systems from any vendor supported by regulatory marketapprovals in the U.S., Europe and Canada.
For further information, pleasecontact:
Dr. George Adams
519-803-6937
Neither the TSX Venture Exchange nor its RegulationServices Provider (as that term is defined in the policies of the TSXVenture Exchange) accepts responsibility for the adequacy or accuracyof this news release.
Forward Looking Statements
This news release contains forward-looking statementsand forward-looking information within the meaning of applicablesecurities laws. The use of any of the words "expect","anticipate", "continue", "estimate","objective", "ongoing", "may","will", "project", "should","believe", "plans", "intends'' and similarexpressions are intended to identify forward-looking information orstatements. The forward-looking statements and information are basedon certain key expectations and assumptions made by the Company.Although the Company believes that the expectations and assumptions onwhich such forward-looking statements and information are based arereasonable, undue reliance should not be placed on the forward-lookingstatements and information because the Company can give no assurancethat they will prove to be correct.
Since forward-looking statements and informationaddress future events and conditions, by their very nature theyinvolve inherent risks and uncertainties. Actual results could differmaterially from those currently anticipated due to a number of factorsand risks. Factors which could materially affect such forward-lookinginformation are described in the risk factors in the Company's mostrecent annual management's discussion and analysis that is availableon the Company's profile on SEDAR at www.sedar.com. Readers arecautioned that the foregoing list of factors is not exhaustive. Theforward-looking statements included in this news release are expresslyqualified by this cautionary statement. The forward-looking statementsand information contained in this news release are made as of the datehereof and the Company undertakes no obligation to update publicly orrevise any forward-looking statements or information, whether as aresult of new information, future events or otherwise, unless sorequired by applicable securities laws.
Copyright (c) 2022 TheNewswire - All rights reserved.